Isofol Medical announces successful Type C meeting with FDA regarding its drug candidate, Modufolin® for treatment of metastatic colorectal cancer
Isofol Medical AB (publ) announces the completion of a successful Type-C meeting with the FDA in preparation for the pivotal study ISO-CC-007, with Modufolin in metastatic colorectal cancer (mCRC).Isofol Medical AB (publ) has conducted a successful Type C meeting with United States Food and Drug Administration (FDA) as a part of of the IND (investigational new drug application) process for Modufolin® in colorectal cancer. The outcome of this successful Type C meeting, represents an important step in the regulatory process and FDA agrees with Isofol and confirms that in order to start the